Filtered By:
Infectious Disease: Hepatitis C

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 11945 results found since Jan 2013.

Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting
CONCLUSION AND SCIENTIFIC SIGNIFICANCE: This study provides new knowledge of previously unexamined associations between comorbidities (e.g., hypertension) and buprenorphine treatment retention. The robust association between cocaine use and poorer buprenorphine retention serves to resolve prior conflicting data in the literature.PMID:35385169 | DOI:10.1111/ajad.13268
Source: American Journal on Addictions - April 6, 2022 Category: Addiction Authors: Mary M Sweeney Laura Prichett Michael I Fingerhood Denis Antoine Annie Umbricht Kelly E Dunn Megan E Buresh Source Type: research

Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.
CONCLUSIONS: HCV infection was associated with higher plasma concentrations of buprenorphine and buprenorphine metabolites. SCIENTIFIC SIGNIFICANCE AND FUTURE DIRECTIONS: Findings suggest the potential for opioid toxicity among HCV-infected patients treated with buprenorphine/naloxone, and possible hepatotoxic effects related to increased buprenorphine exposure. HCV-infected patients receiving buprenorphine may need lower doses to maintain therapeutic plasma concentrations. (Am J Addict 2014;23:34-40). PMID: 24313239 [PubMed - in process]
Source: American Journal on Addictions - December 12, 2013 Category: Addiction Authors: Masson CL, Rainey PM, Moody DE, McCance-Katz EF Tags: Am J Addict Source Type: research

Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study
Conclusion: Compared with buprenorphine monotherapy, the combined buprenorphine and naloxone product was an acceptable alternative pharmacologic treatment for opioid use disorder during pregnancy.
Source: Journal of Addiction Medicine - May 1, 2020 Category: Addiction Tags: Original Research Source Type: research

Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers
Conclusions Severe and moderate hepatic impairment significantly increased exposure of naloxone and to a lesser extent of buprenorphine. Therefore, buprenorphine/naloxone combination products should generally be avoided in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment. However, buprenorphine/naloxone products may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone [Registered at ClinicalTrials.gov as NCT01846455]
Source: Clinical Pharmacokinetics - January 21, 2015 Category: Drugs & Pharmacology Source Type: research

Prenatally buprenorphine-exposed children: health to 3 years of age
Conclusion: We suggest that prenatally buprenorphine-exposed children have several types of problems with their health at toddler age and that they are susceptible to child maltreatment, especially to medical neglect. What is Known: • Buprenorphine is used in the treatment of opioid addiction in pregnancy. Prenatally buprenorphine-exposed newborns develop neonatal abstinence syndrome (NAS) in about 60 % of cases. Data on the health and maltreatment of these children after neonatal age are limited. ...
Source: European Journal of Pediatrics - May 23, 2015 Category: Pediatrics Source Type: research

A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
CONCLUSIONS: A rapid sublingual buprenorphine/naloxone micro-induction was successfully used to initiate BUP-XR, thereby eliminating the abstinence period prior to buprenorphine/naloxone administration, shortening the induction period, and minimizing withdrawal. SCIENTIFIC SIGNIFICANCE: This is the first reported case of using rapid micro-induction as a bridge to initiate BUP-XR. By reducing the length of induction to 4 days and minimizing withdrawal, this induction method can make BUP-XR more accessible to patients who would otherwise refuse the medication due to concerns of enduring withdrawal. (Am J Addict 2020;00:...
Source: The American Journal on Addictions - April 28, 2020 Category: Addiction Authors: Azar P, Wong JSH, Jassemi S, Moore E, Vo DX, Nikoo M, Young S Tags: Am J Addict Source Type: research